Summary: Investing in biotech and pharma stocks is certainly not for everyone, as these companies
Summary: Pfizer’s stock is undervalued with a 48% upside potential, supported by robust product pipelines,
Summary: I view Pfizer Inc. as a leader in a defensive sector under temporary ROCE
Summary: PFE’s bullish support has already been observed at the $25s, with the worst seemingly
Summary: Today, I’m upgrading my rating for PFE due to several positive trends, both within
Summary: Pfizer continues to transition to a strong future with reduced Covid drug sales. The
Summary: Despite Wall Street’s continued conservatism regarding its business prospects, Pfizer beat analysts’ expectations for
Summary: I initiated a “Buy” rating on Pfizer stock in February 2024, and since then,
Summary: Pfizer investors are enjoying their recent run as PFE stock has outperformed its peers
Summary: Pfizer yields 5.57% with a B- dividend safety rating, known for Eliquis and Xeljanz.